PriceTargets.com logo

DBV Technologies - DBVT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $40.25
  • Forecasted Upside: 102.57%
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 2 Strong Buy Ratings
$19.87 As of 05/1/2026 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for DBVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DBV Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DBVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DBVT

Analyst Price Target is $40.25
▲ +102.57% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for DBV Technologies in the last 3 months. The average price target is $40.25, with a high forecast of $55.00 and a low forecast of $7.25. The average price target represents a 102.57% upside from the last price of $19.87.

This chart shows the closing price for DBVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in DBV Technologies. This rating has held steady since November 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/6/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
2/2/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
4/3/2026
  • 2 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 2 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/1/2026CitigroupReiterated RatingOutperform ➝ Outperform
5/1/2026Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$47.00 ➝ $55.00
3/27/2026Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$45.00 ➝ $47.00
3/27/2026GuggenheimReiterated RatingBuy ➝ Buy$51.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/18/2025HC WainwrightSet Target$40.00
12/17/2025Cantor FitzgeraldSet Target$48.00
12/17/2025CitigroupReiterated RatingOutperform ➝ Outperform
12/17/2025GuggenheimReiterated RatingBuy ➝ Buy$35.00 ➝ $51.00
12/17/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$21.00 ➝ $45.00
12/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $35.00
12/15/2025Cantor FitzgeraldUpgradeStrong-Buy
12/14/2025Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$42.00 ➝ $42.00
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/3/2025GuggenheimInitiated CoverageBuy$35.00
12/3/2025GuggenheimInitiated CoverageBuy$35.00
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/29/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $20.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/29/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/26/2025Lifesci CapitalUpgradeStrong-Buy
6/26/2025Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$21.00
5/29/2025The Goldman Sachs GroupUpgradeSell$7.25
5/27/2025CitigroupReiterated RatingOutperform ➝ Outperform
5/27/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/5/2025HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $16.00
5/1/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.00
1/10/2025Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$10.00 ➝ $10.00
12/10/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$10.00 ➝ $10.00
10/24/2024HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $35.00
9/24/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$25.00 ➝ $25.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
7/31/2024Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$20.00 ➝ $25.00
5/8/2024HC WainwrightLower TargetBuy ➝ Buy$100.00 ➝ $50.00
2/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$100.00
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00
11/2/2023The Goldman Sachs GroupLower TargetSell ➝ Sell$13.00 ➝ $10.00
8/1/2023Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$40.00
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$100.00
3/3/2023Citizens JmpReiterated RatingMarket Outperform$40.00
3/3/2023HC WainwrightReiterated RatingBuy$100.00
1/4/2023Societe GeneraleUpgradeHold ➝ Buy
12/16/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell
8/4/2022Kepler Capital MarketsUpgradeHold ➝ Buy€60.00
6/8/2022Citizens JmpReiterated RatingBuy$50.00
5/9/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$60.00 ➝ $15.00
5/3/2022HC WainwrightReiterated RatingBuy$100.00
3/4/2022HC WainwrightReiterated RatingBuy$100.00
1/19/2022Societe GeneraleDowngradeBuy ➝ Hold
12/22/2021UBS GroupDowngradeBuy ➝ Neutral
12/21/2021HC WainwrightLower TargetBuy$140.00 ➝ $100.00
12/21/2021Citizens JmpLower TargetMarket Outperform$80.00 ➝ $50.00
10/15/2021Citizens JmpReiterated RatingBuy$110.00
9/14/2021Societe GeneraleUpgradeHold ➝ Buy
5/4/2021Societe GeneraleUpgradeSell ➝ Hold
(Data available from 5/4/2021 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025
  • 8 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/4/2026

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

DBV Technologies logo
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Read More

Today's Range

Now: $19.87
Low: $19.80
High: $21.20

50 Day Range

MA: $20.89
Low: $19.09
High: $23.54

52 Week Range

Now: $19.87
Low: $7.53
High: $26.18

Volume

153,642 shs

Average Volume

204,838 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of DBV Technologies?

The following Wall Street sell-side analysts have issued stock ratings on DBV Technologies in the last year: Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Guggenheim, HC Wainwright, Lifesci Capital, The Goldman Sachs Group, Inc., Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for DBVT.

What is the current price target for DBV Technologies?

0 Wall Street analysts have set twelve-month price targets for DBV Technologies in the last year. Their average twelve-month price target is $40.25, suggesting a possible upside of 102.6%. Citizens Jmp has the highest price target set, predicting DBVT will reach $55.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $7.25 for DBV Technologies in the next year.
View the latest price targets for DBVT.

What is the current consensus analyst rating for DBV Technologies?

DBV Technologies currently has 2 sell ratings, 1 hold rating, 4 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DBVT.

What other companies compete with DBV Technologies?

Other companies that are similar to DBV Technologies include Dianthus Therapeutics, Legend Biotech, Indivior, Anbio Biotechnology and Kiniksa Pharmaceuticals International. Learn More about companies similar to DBV Technologies.

How do I contact DBV Technologies' investor relations team?

DBV Technologies' physical mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company's listed phone number is (315) 542-7878 and its investor relations email address is [email protected]. The official website for DBV Technologies is www.dbv-technologies.com. Learn More about contacing DBV Technologies investor relations.